Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

AbbVie, in partnership with Ironwood Pharmaceuticals, completed a Phase 2 clinical trial of linaclotide for pediatric ...

AbbVie Inc. (NYSE:ABBV) is one of the 10 undervalued blue chip stocks analysts recommend for smart investing. On June 18, the ...

AbbVie’s stock danced a volatile jig on June 20th, teasing both bulls and bears before landing barely changed at $185.30. The ...

AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

US stocks in focus after Iran attacked US bases in Qatar. Investors often turn to dividend stocks for stability amidst ...

AbbVie Inc. (NYSE: ABBV) is one of the best dividend stocks for a bear market. The company holds the title of a Dividend King ...

Antibody drug conjugates, or ADCs, are still holding on to their spot as one of the hottest areas in cancer care—and AbbVie, ...

AbbVie's atogepant showed fewer side effects and greater efficacy than topiramate in a Phase 3 migraine prevention trial.

Health and Human Services Secretary Robert F. Kennedy Jr. wants to make it harder and more expensive for drug companies to advertise to patients.

Shares of AbbVie Inc. ABBV slid 2.82% to $185.48 Tuesday, on what proved to be an all-around poor trading session for the ...

Limiting pharma ads would be a major win for Health and Human Services Secretary Robert F. Kennedy Jr. He’s long wanted to ...